Read more about the article Oramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2.
Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)

Oramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2.

Continue ReadingOramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2.
Read more about the article Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2
Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)

Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2

Continue ReadingOramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2
Read more about the article Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2.
Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)

Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2.

Continue ReadingOramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2.
Read more about the article BioLineRx Ltd.: Company is on track with its execution of multiple clinical development programs for the Company’s lead project – BL-8040; Sufficient funds to support this development; Stock price target raised to NIS 5.15

BioLineRx Ltd.: Company is on track with its execution of multiple clinical development programs for the Company’s lead project – BL-8040; Sufficient funds to support this development; Stock price target raised to NIS 5.15

Continue ReadingBioLineRx Ltd.: Company is on track with its execution of multiple clinical development programs for the Company’s lead project – BL-8040; Sufficient funds to support this development; Stock price target raised to NIS 5.15
Read more about the article BioLineRx Ltd.: Continued execution of multiple clinical development programs for the Company’s lead project – BL-8040; Investment by a principal investor reflects confidence in the company’s strategy. Target Price unchanged.

BioLineRx Ltd.: Continued execution of multiple clinical development programs for the Company’s lead project – BL-8040; Investment by a principal investor reflects confidence in the company’s strategy. Target Price unchanged.

Continue ReadingBioLineRx Ltd.: Continued execution of multiple clinical development programs for the Company’s lead project – BL-8040; Investment by a principal investor reflects confidence in the company’s strategy. Target Price unchanged.
Read more about the article BiolineRX is on track with its execution of multiple clinical development programs for the Company’s lead product – BL-8040; the company has sufficient cash until H1-2020; target price remains unchanged as company’s clinical development is in line with our expectations

BiolineRX is on track with its execution of multiple clinical development programs for the Company’s lead product – BL-8040; the company has sufficient cash until H1-2020; target price remains unchanged as company’s clinical development is in line with our expectations

Continue ReadingBiolineRX is on track with its execution of multiple clinical development programs for the Company’s lead product – BL-8040; the company has sufficient cash until H1-2020; target price remains unchanged as company’s clinical development is in line with our expectations